Connie Medlen
University of Pretoria, South Africa

Constance Elizabeth J. van Medlen was appointed as a Senior Lecturer by the University of Pretoria in the Department of Immunology in October 1979. During the following six years, she was awarded the M.S. and Ph.D. degrees in immunology by the University of Pretoria. She was promoted to an Associate Professor in 1990 and Full Professor in 1995. At the beginning of 2002, she was transferred to the Department of Pharmacology. Her responsibilities in this department include teaching postgraduates in immunology and supervision of research programs. She is the author or coauthor of 98 scientific papers, eight international patents, and three South African patents. She was also responsible for the release of a product on the market with anti-inflammatory properties. She is the Chairperson of the M.S. protocol committee and a Member of the Research and the Faculty Day committees of the Faculty of Health Sciences, University of Pretoria, as well as the Animal Use and Care Committee. Her research activities are funded by private companies as well as by CANSA, THRIP, NRF, BioPAD, and MRC. During 1998, she was appointed as a Research Coordinator/Director of a CANSA funded consortium entitled “The anti-cancer drug development consortium.” Her primary research interests are experimental immunopharmacology, flow cytometry, and drug development. Thanks to the electronic media, she has managed to build up a network of research collaborators, at national and international levels, working together on various aspects of her research. She received various Best Publication awards from the Faculty of Health Sciences, University of Pretoria.

Biography Updated on 5 July 2007

Personal Home Page

http://www.up.ac.za/academic/medicine/pharmacology/06_staff/connie_cv.htm

Articles in Scholarly Journals [Incomplete List]

  1. A cytotoxic bis(carbene)gold(i) complex of ferrocenyl complexes: synthesis and structural characterisation
    New Journal of Chemistry, vol. 32, no. 3, p. 533, 2008
  2. Macromolecular Antiproliferative Agents Featuring Dicarboxylato-Chelated Platinum
    Journal of Inorganic and Organometallic Polymers and Materials, vol. 18, no. 1, pp. 111–123, 2008
  3. The In Vitro Antitumour Activity of Novel, Mitochondrial-Interactive, Gold-Based Lipophilic Cations
    Metal-Based Drugs, vol. 2008, Article ID 864653, 5 pages, 2008
  4. Synthesis of new 7-chloroquinolinyl thioureas and their biological investigation as potential antimalarial and anticancer agents
    Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 20, pp. 5683–5685, 2007
  5. Brown Coal Derived Humate Inhibits Contact Hypersensitivity; An Efficacy, Toxicity and Teratogenicity Study in Rats
    Inflammation, vol. 30, no. 5, pp. 148–152, 2007
  6. Screening of Venda medicinal plants for antifungal activity against Candida albicans
    South African Journal of Botany, vol. 73, no. 2, pp. 256–258, 2007
  7. Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium tuberculosis
    Phytomedicine, vol. 13, no. 9-10, pp. 630–635, 2006
  8. Synthesis, characterization and antitumor properties of titanocene derivatives with thiophene containing ligands
    Journal of Organometallic Chemistry, vol. 690, no. 1, pp. 117–125, 2005
  9. Gold(I) and silver(I) complexes of 2,3-bis(diphenylphosphino)maleic acid: Structural studies and antitumour activity
    Inorganica Chimica Acta, vol. 358, no. 14, pp. 4237–4246, 2005
  10. Comparison of the effects of cisplatin and a novel platinum polymer conjugate on the production of reactive oxygen species by human neutrophils in vitro
    Drug Development Research, vol. 66, no. 3, pp. 204–209, 2005
  11. Evaluation of cisplatin and a novel platinum polymer conjugate for drug toxicity and drug distribution in mice
    Anti-Cancer Drugs, vol. 16, no. 5, pp. 501–506, 2005
  12. Characterization of Intracellular Activity of Antitubercular Constituents the Roots of Euclea natalensis
    Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), vol. 43, no. 4, pp. 353–357, 2005
  13. Antimicrobial Activities of Seven Novel Tetramethylpiperidine-Substituted Phenazines against Multiple-Drug-Resistant Gram-Positive Bacteria
    Chemotherapy, vol. 51, no. 5, pp. 263–267, 2005
  14. Studies on antibacterial, antioxidant and fibroblast growth stimulation of wound healing remedies from South Africa
    Journal of Ethnopharmacology, vol. 95, no. 2-3, pp. 353–357, 2004
  15. An In Vitro Investigation of the Anti-Inflammatory Properties of Potassium Humate
    Inflammation, vol. 28, no. 3, pp. 169–174, 2004
  16. Investigation of the Anti-HIV Properties of Oxihumate
    Chemotherapy, vol. 48, no. 3, pp. 138–143, 2002
  17. Phase I trial with oral oxihumate in HIV-infected patients
    Drug Development Research, vol. 57, no. 1, pp. 34–39, 2002
  18. Pilot study to evaluate the safety and therapeutic efficacy of topical oxifulvic acid in atopic volunteers
    Drug Development Research, vol. 57, no. 1, pp. 40–43, 2002
  19. Topical application of oxifulvic acid suppresses the cutaneous immune response in mice
    Drug Development Research, vol. 53, no. 1, pp. 29–32, 2001
  20. Investigational New Drugs, vol. 19, no. 3, pp. 211–217, 2001
  21. Vitamin E attenuates the injurious effects of bioactive phospholipids on human ciliated epithelium <I>in vitro</I>
    European Respiratory Journal, vol. 18, no. 1, pp. 122–129, 2001
  22. Ca2+ mobilization induced by ?-hexachlorocyclohexane in Madin Darby canine kidney cells
    Drug Development Research, vol. 50, no. 2, pp. 186–192, 2000
  23. An in vitro investigation of the antimicrobial activity of oxifulvic acid
    Journal of Antimicrobial Chemotherapy, vol. 46, no. 5, pp. 853–854, 2000
  24. In vitro Investigation of the Antimicrobial Activities of Novel Tetramethylpiperidine- Substituted Phenazines against <i>Mycobacterium tuberculosis</i>
    Chemotherapy, vol. 46, no. 1, pp. 43–48, 2000
  25. Cytotoxic activity of two polyaspartamide- based monoamineplatinum(II) conjugates against the HeLa cancer cell line
    Applied Organometallic Chemistry, vol. 13, no. 3, pp. 189–194, 1999
  26. B4112, a Novel Tetramethylpiperidine-Substituted Phenazine That Inhibits the Proliferation of Multidrug-Resistant Cancer Cell Lines
    Annals of the New York Academy of Sciences, vol. 886, no. 1 ANTICANCER MO, pp. 280–282, 1999
  27. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis
    European Respiratory Journal, vol. 12, no. 2, pp. 351–356, 1998
  28. Antineoplastic activity of polyaspartamide-ferrocene conjugates
    Applied Organometallic Chemistry, vol. 12, no. 12, pp. 793–799, 1998
  29. α-Tocopherol antagonizes the multidrug-resistance-reversal activity of cyclosporin A, verapamil, GF120918, clofazimine and B669
    Cancer Letters, vol. 127, no. 1-2, pp. 107–112, 1998
  30. Annals of Oncology, vol. 9, no. 2, pp. 217–219, 1998
  31. A time-kill study to evaluate the in-vitro activity of clofazimine in combination with cefotaxime against a penicillin- and cefotaxime- resistant strain of Streptococcus pneumoniae
    Journal of Antimicrobial Chemotherapy, vol. 40, no. 4, pp. 602–604, 1997
  32. Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multidrug resistant cancer cell line
    Anti-Cancer Drugs, vol. 8, no. 7, pp. 708–713, 1997
  33. Riminophenazine compounds: pharmacology and anti-neoplastic potential
    Critical Reviews in Oncology/Hematology, vol. 25, no. 1, pp. 55–67, 1997
  34. Journal of Inorganic and Organometallic Polymers, vol. 7, no. 4, pp. 217–231, 1997
  35. The riminophenazines, clofazimine and B669, inhibit potassium transport in Gram-positive bacteria by a lysophospholipid-dependent mechanism
    Journal of Antimicrobial Chemotherapy, vol. 38, no. 3, pp. 349–362, 1996
  36. Corrigendum to “chemosensitizing interactions of clofazimine and B669 with human K562 erythroleukaemia cells with varying levels of expression of P-glycoprotein” Cancer Letters 99 (1996) 73–78
    Cancer Letters, vol. 101, no. 2, p. 263, 1996
  37. Chemosensitizing interactions of clofazimine and B669 with human K562 erythroleukaemia cells with varying levels of expression of P-glycoprotein
    Cancer Letters, vol. 99, no. 1, pp. 73–78, 1996
  38. Augmentative inhibition of lymphocyte proliferation by cyclosporin A combined with the riminophenazine compounds clofazimine and B669
    Inflammation Research, vol. 44, no. 9, pp. 379–385, 1995
  39. α-Tocopherol Prevents Cyclosporine A-Mediated Activation of Phospholipase A2 and Inhibition of Na+, K+-Adenosine Triphosphatase Activity in Cultured Hamster Renal Tubular Cells
    Toxicology and Applied Pharmacology, vol. 125, no. 2, pp. 176–183, 1994
  40. The riminophenazine agents clofazimine and B669 reverse acquired multidrug resistance in a human lung cancer cell line
    Cancer Letters, vol. 85, no. 1, pp. 59–63, 1994
  41. Vitamin E protects mononuclear leucocyte DNA against damage mediated by phagocyte-derived oxidants
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 288, no. 2, pp. 257–262, 1993
  42. Hypochlorous acid potentiates hydrogen peroxide-mediated DNA-strand breaks in human mononuclear leucocytes
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 265, no. 2, pp. 255–261, 1992
  43. Inactivation of poly(ADP-ribose) polymerase by hypochlorous acid
    Free Radical Biology and Medicine, vol. 11, no. 3, pp. 285–291, 1991
  44. Pro-oxidative interactions of dithranol with human phagocytes promote oxidative damage to DNA of bystander leucocytes
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 247, no. 1, pp. 39–44, 1991
  45. Investigation of the relationships between plasma levels of ascorbate, vitamin E and β-carotene and the frequency of sister-chromatid exchanges and release of reactive oxidants by blood leucocytes from cigarette smoker
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 215, no. 2, pp. 167–172, 1989
  46. Clofazimine-mediated regulation of human polymorphonuclear leukocyte migration by pro-oxidative inactivation of both leukoattractants and cellular migratory responsiveness
    International Journal of Immunopharmacology, vol. 8, no. 6, pp. 605–620, 1986
  47. Effects of benoxaprofen on the binding to and inactivation of leucoattractants by human polymorphonuclear leucocytesin vitro
    Agents and Actions, vol. 16, no. 6, pp. 527–534, 1985